Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESENTATION - ENDRA Life Sciences Inc. | ndra_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported)
January 11,
2021
ENDRA
Life Sciences Inc.
(Exact name of registrant as specified in its charter)
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-37969
|
|
26-0579295
|
|
(State or other
jurisdiction of incorporation
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
|
3600 Green Court,
Suite 350 Ann Arbor, MI
|
|
48105
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
|
|
|
|
|
Registrant's
telephone number, including area code
|
|
(734)
335-0468
|
|
|
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant
to Section 12(b) of the Act:
|
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
|
Common
stock, par value $0.0001 per share
|
NDRA
|
The
Nasdaq Stock Market LLC
|
|
Warrants, each to
purchase one shares of Common Stock
|
NDRAW
|
The
Nasdaq Stock Market LLC
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth
company ☑
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operation and Financial Condition.
On
January 11, 2021, ENDRA Life Sciences Inc. (the
“Company”) posted an updated investor presentation on
its website at http://investors.endrainc.com.
The updated investor presentation states that the Company’s
cash balance as of December 31, 2020 was $7.3 million.
This preliminary financial information is based on
information available to the Company as of the date of this Current
Report on Form 8-K and is subject to the completion of the
Company’s year-end financial closing procedures and review by
the Company’s independent registered public accounting
firm.
Forward-Looking Statements
All
statements in this report that are not based on historical fact are
“forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe future plans,
strategies and expectations, can generally be identified by the use
of forward-looking terms such as “believe,”
“expect,” “may,” “will,”
“should,” “could,” “seek,”
“intend,” “plan,” “goal,”
“explore,” “estimate,”
“anticipate” or other comparable terms. Examples of
forward-looking statements include, among others, preliminary
financial information. The forward-looking statements made in this
report speak only as of the date of this report, and the Company
assumes no obligation to update any such forward-looking statements
to reflect actual results or changes in expectations, except as
otherwise required by law.
Item
7.01 Regulation FD Disclosure.
The
information set forth in Item 2.02 of this Current Report on Form
8-K is incorporated herein by reference. The updated investor
presentation is furnished as Exhibit 99.1 to this Current Report on
Form 8-K.
The
information furnished in Items 2.02 and 7.01 of this Current Report
on Form 8-K, including Exhibit 99.1 attached hereto, shall not be
deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference into any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
|
Exhibit
No.
|
Description
|
|
ENDRA Life Sciences
Inc. January 2021 Investor Presentation, furnished
herewith.
|
SIGNATURE
|
|
ENDRA
Life Sciences Inc.
|
|
|
January 11,
2021
|
|
|
|
|
By:
|
/s/ Francois
Michelon
|
|
|
Name:
|
Francois
Michelon
|
|
|
Title:
|
President and Chief
Executive Officer
|